Efficacy and safety of PDE5 inhibitors in middle-aged and old patients with and without hypogonadism.

IF 2.7 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Aging Male Pub Date : 2024-12-01 Epub Date: 2023-12-26 DOI:10.1080/13685538.2023.2288347

Chunlin Wang, Hui Zhang, Fu Wang, Jun Guo, Jianlin Yuan, Guangdong Hou, Ming Gao, Zheng Li, Yan Zhang

{"title":"Efficacy and safety of PDE5 inhibitors in middle-aged and old patients with and without hypogonadism.","authors":"Chunlin Wang, Hui Zhang, Fu Wang, Jun Guo, Jianlin Yuan, Guangdong Hou, Ming Gao, Zheng Li, Yan Zhang","doi":"10.1080/13685538.2023.2288347","DOIUrl":null,"url":null,"abstract":"Purpose: Although several reviews have evaluated the use of PDE5 inhibitors (PDE5i) for treating erectile dysfunction (ED), their specific use in middle-aged and old patients has not been fully evaluated. Given that elderly patients with ED often have a complex combination of systemic and sexual health risk factors, the safety and efficacy of PDE5i in such a context are hereby reviewed.Materials and methods: A thorough examination of existing literature has been conducted on PubMed.Results: PDE5i has good safety and efficacy, but the situation is more complex for patients with hypogonadism than those with normal testosterone levels, with reduced responsiveness to PDE5i. In this case, combination therapy with testosterone is recommended, safe and effective.Conclusions: Eliminating or reducing reversible risk factors and controlling or slowing the development of irreversible factors is an important foundation for using PDE5i to treat ED in all patients, especially middle-aged and elderly ones.","PeriodicalId":55542,"journal":{"name":"Aging Male","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aging Male","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13685538.2023.2288347","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/26 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Although several reviews have evaluated the use of PDE5 inhibitors (PDE5i) for treating erectile dysfunction (ED), their specific use in middle-aged and old patients has not been fully evaluated. Given that elderly patients with ED often have a complex combination of systemic and sexual health risk factors, the safety and efficacy of PDE5i in such a context are hereby reviewed.

Materials and methods: A thorough examination of existing literature has been conducted on PubMed.

Results: PDE5i has good safety and efficacy, but the situation is more complex for patients with hypogonadism than those with normal testosterone levels, with reduced responsiveness to PDE5i. In this case, combination therapy with testosterone is recommended, safe and effective.

Conclusions: Eliminating or reducing reversible risk factors and controlling or slowing the development of irreversible factors is an important foundation for using PDE5i to treat ED in all patients, especially middle-aged and elderly ones.

查看原文本刊更多论文

PDE5 抑制剂对伴有或不伴有性腺功能减退症的中老年患者的疗效和安全性。

目的：尽管已有多篇综述对使用PDE5抑制剂（PDE5i）治疗勃起功能障碍（ED）进行了评估，但尚未对其在中老年患者中的具体应用进行全面评估。鉴于患有 ED 的老年患者通常具有复杂的全身性和性健康风险因素组合，本文对 PDE5i 在这种情况下的安全性和有效性进行了综述：结果：PDE5i 具有良好的安全性和有效性：PDE5i具有良好的安全性和有效性，但性腺功能减退症患者的情况比睾酮水平正常的患者更为复杂，他们对PDE5i的反应性降低。在这种情况下，建议与睾酮联合治疗，既安全又有效：消除或减少可逆的危险因素，控制或减缓不可逆因素的发展，是使用PDE5i治疗所有患者（尤其是中老年患者）ED的重要基础。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Aging Male 医学-泌尿学与肾脏学

CiteScore

6.40

自引率

3.80%

发文量

审稿时长

>12 weeks

期刊介绍： The Aging Male , the official journal of the International Society for the Study of the Aging Male, is a multidisciplinary publication covering all aspects of male health throughout the aging process. The Journal is a well-recognized and respected resource for anyone interested in keeping up to date with developments in this field. It is published quarterly in one volume per year. The Journal publishes original peer-reviewed research papers as well as review papers and other appropriate educational material that provide researchers with an integrated perspective on this new, emerging specialty. Areas of interest include, but are not limited to: Diagnosis and treatment of late-onset hypogonadism Metabolic syndrome and related conditions Treatment of erectile dysfunction and related disorders Prostate cancer and benign prostate hyperplasia.